M. Green

发表

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

J. Herndon, Mark R. Green, R. Dillman, 1996, Journal of the National Cancer Institute.

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer.

M. Green, R. Lilenbaum, R. Lilenbaum, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.

B. Freidlin, D. Gandara, F. Shepherd, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer.

S L George, D A Berry, D. Berry, 1994, Statistics in medicine.

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.

D. V. Von Hoff, M. Moore, E. Casper, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

D. V. Von Hoff, M. Moore, H. Burris, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.

J. Herndon, M. Green, G. Clamon, 1996, Lung cancer.

Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.

G. Rosner, R. Schilsky, M. Ratain, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B.

C. Schiffer, H. Preisler, R. Weiss, 1991, Blood.

Anatomical prognostic factors after abdominal perineal resection.

M. Green, B. Walz, E. Lindstrom, 1977, International journal of radiation oncology, biology, physics.

New adjuvant strategies for the management of resectable non-small-cell lung cancer.

M. Green, 1993, Chest.

New directions for chemotherapy in non-small-cell lung cancer.

Mark R. Green, M. Green, 1993, Chest.

Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.

J. Holland, J. Herndon, T. Ahles, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation and chemotherapy for patients with stage III non-small cell lung cancer.

Mark R. Green, M. Green, C. Sherman, 2000, Seminars in radiation oncology.

Clinical studies in non-small cell lung cancer: the CALGB experience.

E. Vokes, M. Green, Mark R. Green, 1998, Cancer investigation.

The role of induction chemotherapy before radiation therapy in non-operative management of stage III NSCLC.

M. Green, 1994, Lung cancer.

Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636.

J. Herndon, S. Seagren, M. Green, 1994, International journal of radiation oncology, biology, physics.

A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B.

J. Herndon, J. Rosenman, W. Eaton, 1994, Cancer investigation.

Does adjuvant chemotherapy decrease distant metastasis formation in patients with non-small cell lung cancer?

M. Green, 1994, Lung cancer.

Pre-operative and post-operative treatments in stage III NSCLC.

R. Ginsberg, O. Brodin, D. Payne, 1994, Lung cancer.

Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report.

R. Arriagada, M. Fukuoka, J. Cox, 1994, Lung cancer.

Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.

A. Lal, J. Urbanic, M. Green, 2001, Seminars in oncology.

High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.

J. Herndon, N. Vogelzang, M. Green, 2001, Lung cancer.

Lung cancer staging and treatment in multidisciplinary trials: Cancer and Leukemia Group B cooperative group approach. Thoracic Surgeons of CALGB.

D. Sugarbaker, C. Reed, W. Nugent, 1999, The Annals of thoracic surgery.

Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107).

A. Dudek, E. Vokes, R. Kratzke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent outcomes for patients with carcinoma of the lung.

R. Dillman, S. Seagren, M. Green, 1991, Cancer investigation.

Staging classification committee.

J. Jett, R. Ginsberg, R. Tsuchiya, 1997, Lung cancer.

Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.

J. Herndon, Mark R. Green, W. Eaton, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and leukemia group B.

J. Holland, T. Ahles, A. Rundle, 1997, Psychotherapy and psychosomatics.

Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group.

D. Sugarbaker, J. Herndon, Mark R. Green, 1995, The Journal of thoracic and cardiovascular surgery.

Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.

N. Choi, D. Mathisen, J. Herndon, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial.

J. Herndon, E. Vokes, M. Kelley, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

R. Govindan, J. Herndon, N. Rizvi, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.

J. Herndon, M. Green, S. Fleishman, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of ifosfamide, mesna, and cisplatin in advanced non‐small cell lung cancer a cancer and leukemia group B study

J. Herndon, Mark R. Green, M. Green, 1993, Cancer.

Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies.

M. Green, R. Lilenbaum, D. MacManus, 1998, American journal of clinical oncology.

A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.

J. Herndon, Mark R. Green, M. Green, 1997, Controlled clinical trials.

Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.

J. Herndon, D. Hollis, W. Eaton, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic lymphocytic leukemia and other chronic lymphoid proliferations: surface marker phenotypes and clinical correlations.

R. Dillman, M. Green, I. Royston, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633.

R. Schilsky, D. Sugarbaker, D. Harpole, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.

J. Herndon, E. Vokes, M. Kelley, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine safety overview.

M. Green, 1996, Seminars in oncology.

Chemotherapy of head and neck cancer.

M. Green, Mark R. Green, 1978, Head & neck surgery.

Co‐ordinated over‐expression of the MRP and γ‐glutamylcysteine synthetase genes, but not MRD1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines

Mark R. Green, B. Ogretmen, A. Safa, 1998, International journal of cancer.

Chemotherapy and radiation in the nonoperative management of stage III non-small-cell lung cancer: the right chemotherapy works in the right setting.

M. Green, 1993, Important advances in oncology.

Carboplatin in non-small cell lung cancer: an update on the Cancer and Leukemia Group B experience.

K. Propert, M. Green, G. Clamon, 1992, Seminars in oncology.

Multimodal therapy for solid tumors.

M. Green, 1994, The New England journal of medicine.

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

J. Herndon, N. Vogelzang, M. Green, 2001, Lung cancer.

Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study.

M. Green, J. Aisner, R. Carey, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multimodality therapy for non-small-cell lung cancer.

M. Green, R. Lilenbaum, 1994, Oncology.

Unresectable stage III non-small-cell lung cancer: lessons and directions from clinical trials research.

M. Green, 1991, Journal of the National Cancer Institute.

Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.

M. Green, C. Sherman, C. R. Rocha Lima, 2000, Oncology.

Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.

M. Green, F. Brescia, C. Sherman, 2001, Oncology.

G. Rosner, R. Schilsky, M. Ratain, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immediate impact of the FOLFIRINOX phase III data reported at the 2010 ASCO Annual Meeting on prescribing plans of American oncology physicians for patients with metastatic pancreas cancer (MPC).

J. Marshall, J. Bendell, M. Green, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).

J. Herndon, D. Hollis, S. Luikart, 1997, American journal of clinical oncology.

Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.

S. Howell, M. Green, M. Markman, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: a Cancer and Leukemia Group B study.

M. Costanza, M. Green, H. Kreisman, 1990, European journal of cancer.

Overview of MTA in the treatment of non-small cell lung cancer.

P. Postmus, M. Green, 1999, Seminars in oncology.

Induction therapy for stage III NSCLC: a consensus report.

R. Ginsberg, M. Fukuoka, A. Ardizzoni, 1994, Lung cancer.

A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study.

J. Herndon, S. Luikart, C. Cirrincione, 1996, Lung cancer.

Docetaxel followed by gemcitabine and irinotecan in solid tumors.

J. Urbanic, M. Green, F. Brescia, 2001, Oncology.

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B.

A. Kramar, M. Green, M. Stoopler, 1990, Medical and pediatric oncology.

Multimodality therapy in unresected stage III non-small cell lung cancer: the American Cooperative Groups' Experience.

M. Green, 1995, Lung cancer.

Cytarabine-cis-platin interactions in patients with advanced cancer.

R. Schilsky, M. Green, J. Anderson, 1985, Seminars in oncology.

Intensity of neoadjuvant therapy in resectable non-small cell lung cancer.

M. Green, J. Barkley, 1997, Lung cancer.

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.

K. Propert, R. Dillman, S. Seagren, 1990, The New England journal of medicine.

A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer.

O. Bogler, I. Newsham, Mark R. Green, 1999, Cancer research.

A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue.

T. Shea, A. Storniolo, M. Green, 1992, Seminars in oncology.

Irinotecan in the management of patients with pancreatic cancer.

A. Safa, M. Green, M. Harper, 2000, Oncology.

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

M J Hawkins, Mark R. Green, M. Green, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B.

C. Schiffer, H. Preisler, R. Weiss, 1991, Blood.

Combination intracavitary chemotherapy for malignant pleural disease.

S. Howell, M. Green, M. Markman, 1984, Cancer drug delivery.

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

E. Casper, R. Heelan, M. Green, 2004, Investigational New Drugs.

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.

J. Herndon, D. Hollis, M. Green, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas

M. Lunning, M. Green, Michael R. Green, 2015, Blood Cancer Journal.

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

J. Herndon, Mark R. Green, N. Vogelzang, 1998, Chest.

Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633.

R. Schilsky, D. Sugarbaker, J. Herndon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines.

A. Safa, M. Green, C. R. Rocha Lima, 1999, Anticancer research.

Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.

A. Safa, M. Green, J. Eckardt, 1999, Seminars in oncology.

Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.

J. Herndon, E. Vokes, J. Atkins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Adenocarcinoma of the fallopian tube: report of a case with an unusual pattern of metastasis and response to combination chemotherapy.

M. Green, J. Young, C. Kossman, 1984, Gynecologic oncology.

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.

K. Propert, N. Nissen, E. Henderson, 1992, The New England journal of medicine.

Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody.

R. Miller, Mark R. Green, B. Parker, 1990, Cancer research.

Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

J. Herndon, M. Green, G. Clamon, 1993, Journal of the National Cancer Institute.

Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.

J. W. Box, J. Herndon, M. Green, 2001, Lung cancer.

Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.

D. Sugarbaker, J. Herndon, Mark R. Green, 1998, Lung cancer.

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

M. Socinski, J. Herndon, E. Vokes, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer.

M. Green, R. Gams, I. Shemano, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.

G. Peters, F. Shepherd, L. Crinò, 1998, Seminars in oncology.

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.

J. Herndon, N. Vogelzang, M. Green, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633.

D. Sugarbaker, J. Herndon, E. Vokes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of high-dose 24-hour continuous intravenous 5-fluorouracil for advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.

M. Citron, K. Propert, M. Green, 1992, Cancer investigation.

Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.

J. Herndon, J. Rosenman, M. Green, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of 4'-deoxydoxorubicin (DxDx) in non-small cell lung cancer: a Cancer and Leukemia Group B Trial.

K. Propert, R. Weiss, M. Green, 1988, Medical and pediatric oncology.

Accelerated radiotherapy followed by chemotherapy for locally recurrent small-cell carcinoma of the lung. A phase II study of Cancer and Leukemia Group B.

N. Choi, K. Propert, W. Eaton, 1987, International journal of radiation oncology, biology, physics.

Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer.

J. Herndon, M. Green, G. Clamon, 2001, Clinical lung cancer.

Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience.

J. Herndon, R. Dillman, M. Green, 1994, Seminars in oncology.

Non-cross-resistant chemotherapy and consolidation radiotherapy for small cell carcinoma of the lung.

R. Dillman, S. Seagren, M. Green, 1982, Cancer treatment reports.

Issues at the cutting edge in stage III non-small-cell lung cancer.

M. Green, R. Lilenbaum, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

AMOPLACE treatment of intermediate-grade and high-grade malignant lymphoma: a Cancer and Leukemia Group B study.

B. Parker, M. Green, A. Gottlieb, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B.

J. Herndon, E. Vokes, M. Green, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Stage IIIA category of non-small-cell lung cancer: a new proposal.

M. Green, R. Lilenbaum, 1994, Journal of the National Cancer Institute.

A phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies.

M. Green, R. Lilenbaum, D. MacManus, 1995, Seminars in oncology.

Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial.

M. Edelman, P. Janne, J. Herndon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105.

M. Socinski, E. Vokes, J. Bogart, 2006, Journal of Clinical Oncology.

Long-term follow-up of patients with locally advanced or metastatic thymic malignancies: The Eastern Cooperative Oncology Group (ECOG) experience.

R. Livingston, C. Langer, M. Green, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed?

M. Green, C. Sherman, C. R. Rocha Lima, 1999, Chest.

A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.

M. Green, G. Clamon, J. Crawford, 1997, Seminars in oncology.

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.

J. Herndon, G. Strauss, N. Vogelzang, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of toremifene in patients with advanced cancer.

D. Haller, J. Hamm, D. Tormey, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Future randomized trials for non small-cell lung cancer.

M. Green, 2000, Clinical lung cancer.

Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study.

J. Herndon, C. Cirrincione, M. Green, 1995, Lung cancer.

Cisplatin in patients with gastric cancer: a Cancer and Leukemia Group B phase II study.

P. Schein, R. Mick, M. Green, 1986, Cancer treatment reports.

Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).

G. Rosner, R. Schilsky, M. Ratain, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

W. Miller, Mark R. Green, M. Green, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

J. Herndon, E. Vokes, M. Kelley, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.

D. Carbone, D. Gandara, E. Vokes, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.

J. Ware, K. Propert, W. Eaton, 1987, The New England journal of medicine.

Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients.

D. Spiegelman, W. Eaton, M. Green, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bisantrene in non-small cell lung cancer: a phase II trial of the Cancer and Leukemia Group B.

K. Propert, M. Green, R. Comis, 1986, Cancer treatment reports.

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.

N. Choi, J. Herndon, J. Rosenman, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer.

J. Herndon, E. Vokes, M. Green, 1997, Seminars in Oncology.

Phase II trial of capecitabine and docetaxel as second line therapy for locally advanced and metastatic pancreatic cancer

E. Roman, G. Lopes, M. Green, 2007 .

Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203.

M. Edelman, E. Vokes, R. Kratzke, 2006, Journal of Clinical Oncology.